Theralase Technologies (TSXV: TLT) Revenue
Pharmaceutical Manufacturing • 
Toronto, Ontario, Canada • 21-50 Employees
Theralase Technologies (TSXV: TLT) revenue & valuation
| Annual revenue | $692,636 |
| Revenue per employee | $21,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $2,300,000 |
| Total funding | $3,893,800 |
Key Contacts at Theralase Technologies (TSXV: TLT)
Guy Anderson
Director
Kyle Shantz
Director Of Global Sales
Company overview
| Headquarters | 41 Hollinger Road, Toronto, ON M4B 3G4, CA |
| Phone number | +18668435273 |
| Website | |
| NAICS | 3254 |
| Keywords | Healthcare, Pharmaceutical, Medical Device, Cancer Research, Photodynamic Compounds, Anti-Cancer, Bladdercancer |
| Founded | 1994 |
| Employees | 21-50 |
| Socials |
Theralase Technologies (TSXV: TLT) Email Formats
Theralase Technologies (TSXV: TLT) uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@theralase.com), used 62.5% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@theralase.com | 62.5% |
{first name} | john@theralase.com | 12.5% |
{last name}{last name} | doedoe@theralase.com | 12.5% |
{first initial} | j@theralase.com | 6.2% |
{first name}{last name} | johndoe@theralase.com | 6.2% |
About Theralase Technologies (TSXV: TLT)
Theralase® Technologies is a Canadian clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers. We strive to continuously improve the quality of life for those afflicted with cancer by focusing our research and development on preventing, alleviating and treating diseases. Serving our higher purpose to bring hope for cancer treatments to light. Founded in 1994, Theralase’s operations are divided into two divisions: the production of therapeutic laser technology for commercial applications, and the research and development of laser-based technologies for the destruction of cancer cells and other disease states. Theralase® is focused on the discovering, developing and aiming for commercialization of Anti-Cancer therapies using light-activated PhotoDynamic Compounds and their associated drug formulations to safely and effectively treat patients afflicted with cancer.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Theralase Technologies (TSXV: TLT) has 18 employees across 4 departments.
Departments
Number of employees
Funding Data
Explore Theralase Technologies (TSXV: TLT)'s funding history, including investment rounds, total capital raised, and key backers.
Funding Date | Round | Amount | Link to Article |
|---|---|---|---|
| 2023-12-17 | 14 | $852,600 | |
| 2024-05-24 | 14 | $548,300 | |
| 2024-08-08 | 14 | $568,400 | |
| 2024-10-24 | 14 | $496,500 | |
| 2025-04-11 | 14 | $214,900 | |
| 2025-05-14 | 14 | $302,000 | |
| 2025-07-17 | 14 | $420,700 | |
| 2025-08-28 | 14 | $490,400 |
Funding Insights
$3,893,800
Total funding amount
$490,400
Most recent funding amount
8
Number of funding rounds
United States
Poland
Spain
Germany
Czechia
Frequently asked questions
4.8
40,000 users
